Brainstorm Cell Therapeutics Ltd. has completed a second tranche of private placement funding, securing an additional $1 million to bring total capital raised in February 2026 to $2 million. The common stock was priced at $0.60 per share, with accompanying warrants issued at 120% coverage and an exercise price of $1.00 per share.
The biotech company intends to allocate the proceeds toward general working capital needs, regulatory initiatives, and preparatory activities for its Phase 3b clinical trial of NurOwn, its investigational cell-based therapy for amyotrophic lateral sclerosis (ALS). The dual-tranche financing structure reflects ongoing investor interest in the company's pipeline advancement during the current funding period.
This capital infusion supports Brainstorm's advancement of its lead therapeutic candidate as it progresses through late-stage clinical development. The company continues to focus on meeting regulatory requirements and operational preparations necessary for the expansion of its ALS treatment program.